Physician profile
Amjad Jalil
NPI 1356391841
$728.36
in general payments reported to CMS, 2019-2025
13 companies · $177 in 2025
The $177 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45.67 · 2021: $232 · 2022: $18.67 · 2023: $134 · 2024: $122 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $268 · Education: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $268.20 |
| Education | $163.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $120.80 | 2021 | |
| Incyte Corporation | $111.08 | 2023-2024 | Monjuvi, Pemazyre |
| Amgen INC. | $99.99 | 2021 | |
| Astellas Pharma US INC | $80.00 | 2025 | |
| Pfizer INC. | $76.20 | 2023-2025 | |
| Karyopharm Therapeutics INC. | $60.54 | 2022-2023 | Xpovio |
| Daiichi Sankyo INC. | $49.68 | 2023-2025 | Enhertu |
| Genentech USA, INC. | $45.67 | 2019 | |
| Stemline Therapeutics INC. | $20.38 | 2024 | Orserdu |
| Seagen INC. | $20.26 | 2023 | Adcetris |
| Eisai INC. | $18.22 | 2025 | |
| Novartis Pharmaceuticals Corporation | $14.50 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $11.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amjad Jalil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.